Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Solid Biosciences: Keep Your Eyes On The Prize Says Top Analyston May 11, 2020 at 1:41 am
Solid Biosciences (SLDB) has reported weaker-than-expected 1Q20 results, with FY GAAP EPS of -$2.91 missing Street consensus by $0.09. However the update for the SGT-001 phase I/II clinical program in ...
- FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q1 2020 Results - Earnings Call Transcripton May 9, 2020 at 2:05 pm
Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Corporate Participants Mike Tung - Investor Relations Enrique Conterno - Ch ...
- Pfizer to review Duchenne gene therapy data May 15on May 8, 2020 at 8:36 am
Pfizer (PFE +0.5%) will host a conference call on Friday, May 15, at 10:00 am ET to review its Duchenne muscular dystrophy (DMD) data presentation at the American Society of Gene and Cell Ther ...
- No respite for Solid Bio's troubled Duchenne program as FDA keeps it on holdon May 8, 2020 at 7:40 am
Solid Biosciences started 2020 by laying off one-third of its staff and “curtailing” most of its R&D to keep its Duchenne muscular dystrophy treatment afloat. Four months later, those efforts have yet ...
- Duchenne Muscular Dystrophy Market is Anticipated to Grow With a CAGR of 31.8% for the Study Period of 2017-2030: DelveInsighton May 7, 2020 at 5:00 am
DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on " Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030 " to its portfolio.
- Paisley man hits the back of the net in aid of Muscular Dystrophy charityon May 5, 2020 at 4:35 am
An inspiring Paisley man scored big for a charity close to his heart by blasting home 26 penalties in his driveway. Connor Colhoun, 23, has raised £750 to support Muscular Dystrophy UK by taking part ...
- Duchenne Muscular Dystrophy Drugs Market Expected to grow at a CAGR of 28.9% by 2026on May 5, 2020 at 3:29 am
Global Duchenne Muscular Dystrophy Drugs Market Size, Status and Forecast 2020-2026 Global Duchenne Muscular Dystrophy Drugs ...
- Duchenne Muscular Dystrophy (DMD) Therapeutics Market set for robust growth by 2016-2024on May 1, 2020 at 2:00 am
Zion Market Research has recently added latest report, titled "Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Set for Rapid Growth, to reach Value USD 20.56 Billion by 2025", which ...
- Global Duchenne Muscular Dystrophy Drugs Industryon April 29, 2020 at 10:35 pm
Reportlinker.com announces the release of the report "Global Duchenne Muscular Dystrophy Drugs Industry" - The shifting dynamics supporting this growth makes it critical for businesses in this space ...
- Duchenne muscular dystrophy: Substituting the next-best proteinon April 23, 2020 at 5:00 pm
Children born with Duchenne muscular dystrophy have a mutation in the X-chromosome gene that would normally code for dystrophin, a protein that provides structural integrity to skeletal muscles.
via Bing News